The use of tumour necrosis factor-α (TNFα) inhibitors was not associated with an increased risk of infection in children with inflammatory bowel disease (IBD), a contrast to previous findings in adult IBD, a study from Denmark showed.
Neither cobalamin intake nor age per se significantly predicts cobalamin status in community-dwelling older adults, a study has shown. Serum folate proves to be a significant predictor of serum cobalamin, whereas diseases such as cancer or inflammatory bowel disease (IBD) may influence cobalamin status.
Probiotic supplements, in addition to diet and exercise, may help obese children lose weight along with improvement in metabolic health compared with those undergoing lifestyle modification alone, according to a pilot study presented at the 58th Annual European Society for Paediatric Endocrinology (ESPE) Meeting held in Vienna, Austria.
Helicobacter pylori treatment for 2 weeks and vitamin or garlic supplementation for 7 years have significantly lowered the risk of death due to gastric cancer during 22.3 years of follow-up, according to a recent study. H pylori treatment and vitamin supplementation are also associated with a reduced incidence of gastric cancer.
Treatment with the combination of pinaverium bromide plus simethicone effectively relieves abdominal pain and bloating in patients with active irritable bowel syndrome (IBS), in addition to improving stool consistency in those with constipation-predominant IBS or a mixed bowel movement pattern, according to the results of a trial.
New drug application approved by US FDA as of 01 - 15 September 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Pembrolizumab improved progression-free survival (PFS) and overall survival (OS) over best supportive care in patients with advanced hepatocellular carcinoma (HCC), according to the phase III KEYNOTE-240* trial, supporting its role as a treatment option for HCC in the second-line setting.
Discontinuation of antitumour necrosis factor (anti-TNF) therapy for perianal Crohn’s disease is highly likely to lead to relapse, with some patients even requiring defunctioning surgery, according to a study conducted across Asia.